Scholarlink

Objective <p>To evaluate the effects of empagliflozin, sitagliptin, and metformin on the glycemic indices and cardiometabolic control of patients with type 2 diabetes mellitus (T2DM).</p> Results <p>The significant changes in FBS from baseline to week 12 were − 23.1, -16.15, and − 15.25&#xa0;mg/dl in the empagliflozin, sitagliptin, and metformin arm, respectively. HbA1C decreased significantly from baseline to week 12 in the empagliflozin, sitagliptin, and metformin arm (-1.8, -1.35, -0.69%). The FBS and HbA1C changes were significant in the empagliflozin group compared to the metformin group (<i>P</i> = 0.027, <i>P</i> = 0.037, respectively). The weight changes were substantial in the empagliflozin group relative to the metformin group (-4.1 vs. -0.90&#xa0;kg; <i>p</i> = 0.044). Compared with the metformin group, the adjusted mean difference in the empagliflozin group was − 12.91&#xa0;mg/dl (95% CI: 31.82, 6; <i>P</i> = 0.001) for triglyceride (TG) levels and 6.47&#xa0;mg/dl (95% CI: 2.93, 10.01; <i>P</i> = 0.010) for high-density lipoprotein (HDL-c) levels. Moreover, empagliflozin led to reductions in SBP about − 8.27&#xa0;mm Hg (95% CI: -13.31, -3.23; <i>P</i> = 0.001) and in DBP about − 13.37&#xa0;mm Hg (95% CI: -16.42, -10.32; <i>P</i> = 0.001) compared with metformin.</p> Trail registration number <p>IRCT. ir (IRCT20191231045959N1).</p> Trail registration date <p>2020-01-19.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Comparison of the effects of empagliflozin and sitagliptin, as an add-on to metformin, on cardio-metabolic and glycemic parameters of patients with type 2 diabetes mellitus: a randomized, double-blind clinical trial

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月31日

查看全文
  • Naimeh Mesri Alamdari,
  • Maryam Barghaman,
  • Neda Roshanravan,
  • Majid Mobasseri,
  • Helda Tutunchi,
  • Amir Baharami,
  • Akbar Aliasgarzadeh,
  • Vahideh Sadra

摘要

Objective

To evaluate the effects of empagliflozin, sitagliptin, and metformin on the glycemic indices and cardiometabolic control of patients with type 2 diabetes mellitus (T2DM).

Results

The significant changes in FBS from baseline to week 12 were − 23.1, -16.15, and − 15.25 mg/dl in the empagliflozin, sitagliptin, and metformin arm, respectively. HbA1C decreased significantly from baseline to week 12 in the empagliflozin, sitagliptin, and metformin arm (-1.8, -1.35, -0.69%). The FBS and HbA1C changes were significant in the empagliflozin group compared to the metformin group (P = 0.027, P = 0.037, respectively). The weight changes were substantial in the empagliflozin group relative to the metformin group (-4.1 vs. -0.90 kg; p = 0.044). Compared with the metformin group, the adjusted mean difference in the empagliflozin group was − 12.91 mg/dl (95% CI: 31.82, 6; P = 0.001) for triglyceride (TG) levels and 6.47 mg/dl (95% CI: 2.93, 10.01; P = 0.010) for high-density lipoprotein (HDL-c) levels. Moreover, empagliflozin led to reductions in SBP about − 8.27 mm Hg (95% CI: -13.31, -3.23; P = 0.001) and in DBP about − 13.37 mm Hg (95% CI: -16.42, -10.32; P = 0.001) compared with metformin.

Trail registration number

IRCT. ir (IRCT20191231045959N1).

Trail registration date

2020-01-19.